About
Technology
Issues
FAQ
Links
Official Page
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.